aim of the Work:The current standard of care for patients with glioblastoma multiforme (GBM) is resection followed by radiotherapy. The median survival time for these patients remains at less than 1 year from initial diagnosis. Temozolomide (TMZ) has shown promising activity in the treatment of malignant gliomas. We conducted a multicenter randomized phase III study comparing the efficacy and safety of TMZ administered concomitantly and sequentially to radiotherapy versus radiotherapy alone in patients with newly diagnosed GBM.
. The current standard of care for patients with GBM is resection followed by radiotherapy. Radiotherapy is necessary because of extensive tumor infiltration into normal brain structures makes resection of the entire primary tumor is impossible 3, 4 . Two large randomized multicenter trials confirmed that radiotherapy provided significant survival advantage 5, 6 . The median survival after surgical resection is about 20 weeks which can be extended to about 36 weeks if additional radiotherapy is received 7 . Despite this documented response essentially 100% of GBM recur within two-years 8 .
The use of adjuvant chemotherapy after surgery or radiotherapy is still controversial but has been shown to increase median survival and time to progression in some trials 9 . Nitrosoureas for many decades were considered the most effective. Malignant glial cells are resistant to many standard chemotherapeutic agents. One of the mechanisms of resistance to the nitrosoureas is the increased expression of the DNA repair enzymes, O6-methylguanine-DNA methyltransferase (MGMT) 10 . Temozolomide (TMZ) is a novel alkylating agent that has proved to be effective in-patients with recurrent GBM [11] [12] [13] . TMZ has been shown to overcome tumor cell resistance to nitrosoureas by depleting MGMT in multicenter phase II trials [14] [15] [16] [17] . In phase I and II clinical trials, TMZ was well tolerated with a favorable toxicity profile, and easily managed noncumultative myelotoxicity 13 .
Interestingly, in vitro experiments with human GBM cell lines have demonstrated that the combination of TMZ and radiotherapy have either synergistic or additive inhibitory effect on tumor cell growth
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. Various schemes and schedules of administration have been investigated, including the neoadjuvant administration of TMZ prior to radiation [19] [20] [21] , and the concomitant administration of TMZ with radiation. Recent reports of phase II studies investigating adjuvant TMZ suggested a potential survival benefit 2, 22-24 .
In our previous pilot study on 18 patients with high grade glioma treated with concomitant postoperative radiotherapy and TMZ, the regimen was safe and tolerable with modest improvement in the median survival and time to progression 24 . However, the results were not promising in GBM compared with these in case of anaplastic astrocytoma (AA). Objective response was achieved in only 45.5% of patients with GBM, the median survival was 10 months and the median time for progression was 6.4 months. This encouraged us to conduct this prospective randomized study to determine if the concomitant use of TMZ and conventionally fractionated irradiation followed by six cycles of adjuvant chemotherapy can improve more the survival with acceptable level of toxicity compared to the standard surgery and postoperative irradiation alone in GBM patients.
patiENts aNd MEthOds
The present work is a randomized study involving patients with pathologically proved GBM (WHO classification 1993) presented to Radiation Oncology Departments-Ain Shams University and Cairo University Hospitals, and Sohag Cancer Center between November 2002 and May 2005. Initial evaluation included: History, and physical examination, comprehensive neurological examination, complete blood count, serum chemistries and chest Xray. Local and regional tumor extents were assessed by gadolinium-enhanced magnetic resonance imaging (MRI) and computed tomographic scan (CT). Patients eligible for this study had histologically confirmed GBM either through open biopsy or stereotactic biopsy. Other eligibility criteria included age of at least 18 years but not more than 70 years, performance status≥ 70 on Karnofsky scale, normal conscious level, adequate hematologic status, liver function, and kidney function, no prior malignancy, no prior radiotherapy or chemotherapy to the brain, no medical condition which could interfere with oral administration of TMZ and no concurrent serious medical illness. Each patient gave written informed consent before entering the study.
Treatment policy:
Eligible patients were randomly assigned to one of two treatment groups either the standard postoperative radiation (group A) or postoperative concomitant TMZ and irradiation followed by 6 cycles TMZ (group B). All the patients were planned to receive radiotherapy after complete healing of the wound and within 2 weeks if surgery was performed. The patients were treated on megavoltage machines (cobalt-60 machine or linear accelerator ≥6 MV photon). Initially the treatment volume included the contrast enhancing lesion and surrounding edema on CT or MRI with a 3cm margin to a total dose of 40 Gy, 2 Gy per fraction, 1 fraction per day, and five days per week. Subsequently, the target volume was reduced to include the enhancing lesion only (without edema) with a 2cm margin to a total dose of 60 Gy/2 Gy/ fraction /6 weeks. Traditionally, the patients were treated through two parallel-opposed portals with the tumor dose calculated at the midline on the central axis of the beam. Anticonvulsant and corticosteroids were administered as needed.
In the chemoradiation group, the patient received concurrently during the radiation course and starting from the first day of radiation, oral TMZ 150 mg/m 2 daily, one hour before breakfasti.e. on empty stomach, for 5 days and repeated after 28 days for two cycles. Four weeks after radiotherapy, patients received adjuvant TMZ (200mg/m 2 ) daily for five days every 28 days for 6 cycles. Laboratory tests including complete blood picture, liver function and kidney function tests, were performed before each cycle of chemotherapy and adjustment of the dose was done according to table 1. The drug was supplied in form of 50 mg, 100mg or 200mg capsules.
The patients were examined generally and neurologically at weekly intervals till the end of the treatment and then every three month after finishing the treatment. Radiological assent by MRI and/or CT were performed 6 weeks after completion of irradiation, every three month as a follow up or if the patient developed progressive neurological symptoms or signs. 
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Evaluation of response:
Response criteria were evaluated from radiological brain imaging (including CT and gadolinium enhanced MRI) together with clinical responses by assessing the patient performance status and steroid dependence after treatment 25 . The responses were then graded into four categories:
Complete response (Cr):
Disappearance of all enhancing tumor on consecutive brain imaging scans, not receiving corticosteroids, and neurologically stable or improved.
partial response (pr):
>50% reduction in size of enhancing tumor on consecutive brain scan, corticosteroid dosage stable or reduced, and neurologically stable or improved.
progressive disease (pd):
>25% increase in the size of enhancing tumor or any new tumor on brain scans, or neurologically worse, and corticosteroid dosage stable or increased.
Stable disease (Sd):
Survival and progression free survival:
Survival was measured from the date of entry into the trial until death or last follow-up. Progression free survival (PFS) was measured from the date of entry into the trial until date of first evidence of disease progression or death from disease. Survival curves were calculated by the Kaplan-Meier method 26 . The comparison of patient characteristics was carried out using the two test for the categoric variables (sex, resection) and using a test for the continuous variables (time from diagnosis to treatment). Age and performance status were transformed to binary variables with cutoff points of 50 years and Karnofsky status of 80, respectively 27 .
Assessment of normal tissue toxicity:
Toxicity was evaluated according to National Cancer institute (NCI) criteria 28 .
REsults
The present study included 44 patients, 21 in radiation group and 23 in chemoradiation group. There were no statistically significant differences in the demographic and baseline characteristics of the two treatment groups ( 
Tumor response:
No recorded complete response in radiation group. Two patients in the chemoradiation group had radiological and clinical complete response. Seven patient (33%) and 10 patients (43.5%) in radiation group and chemoradiation group had partial response respectively, the difference was statistically insignificant. In addition, 9 patients (43%) and 7 patients (30%) in radiation and chemoradiation groups respectively had stable disease, the difference was statitically insignificant. Five patients (24%) in radiation group and 4 patients (17%) in chemoradiation group failed to respond to treatment with disease progression, the difference was statitically insignificant ( 
Survival and progression free survival:
The median follow up was 8 months (range from 5-17 months) in radiation group and 12.8 months (range from 8-30 months) in chemoradiation group. The median survival was 8.5 months (95% confidence internval 6.32-10.68) in radiation group vs. 12.6 months (95% confidence internval 9.41-15.77) in chemoradiation group. The median PFS was 6.3 months (95% confidence internval 3.43-9.23) in radiation group vs. 10.5 months (95% confidence internval 6.99-13.94) in chemoradiation group. The overall survival (Figure 1 ) at 12 months were 23.5% and 43.5% in radiation and in chemoradiation group, respectively, the difference was statistically significant (P=0.04). The PFS (Figure 2 ) at 12 months was 0% in radiation group and 21% chemoradiation group, the difference was statistically significant (P=0.02).
treatment Compliance and toxicity:
Grade three and four toxicity was not recorded in the radiation group. TMZ was safe and tolerable. In the chemoradiation group, 20 patients (87%) received the 2 cycles of TMZ during radiotherapy course. Radiation course interruption, in chemoradiation group, was reported in only 3 patients (13%) due to toxicity with dose reduction to 100mg/m 2 in 2 nd course. During adjuvant TMZ, 19 patients completed the 6 courses of chemotherapy. Four patients received only Two cycles of TMZ, two of them died because of tumor progression after the second cycle and two patients can not tolerate treatment. In the chemoradiation group, the main side effect was myelosuppression. Grade 3/4 hematologic toxicity was documented in three patients (13%) during the concomitant course and in 6 patients (26%) during the adjuvant TMZ course as shown in table 5. 
prognostic factors:
A univariate analysis to test the effect of different prognostic factors on overall survival for patients in chemoradiation group (Table 4) were a trend towards better overall survival for young patients (<50 years old), patients with good performance status (i.e. more than 80 on Karnofsky scale), and for patients underwent debulking surgery but the differences were not statistically significant.
During the concomitant administration of radiation and TMZ, grade 3/4 leukopenia demonstrated in one patients (4.3%) and grade 3/4 thrombocytopenia in two patients (8.7%) Grade 3/4 leukopenia during the adjuvant course was observed in two patients (8.7%) and grade 3/4 thrombocytopenia was observed in four patients (17.4%). In the combined-therapy group, two patients (8.7%) experienced grade 3/4 treatment-related nausea and vomiting during the adjuvant course.
disCussiON
Glioblastoma multiforme (GBM) has a grave prognosis with relapse inevitably following surgery and radiation therapy. Many systemic agents have been explored in the treatment of GBM with the aim of improving outcome [29] [30] [31] .
Of the various chemotherapeutic agents tested, nitrosoureas for many decades are considered the most effective with a reported response rate between 10%-40%. When administered in an adjuvant setting, their benefit in term of survival is small [32] [33] [34] [35] and in some studies, non existent [29] [30] [31] [32] [33] [34] [35] [36] [37] . The benefit of adjuvant nitrosourea based chemotherapy in patients with high grade gliomas has been confirmed in two large metaanalyses [33] [34] [35] . These meta-analyses suggested only 6% to 10% increase in the proportion of patients surviving for 1 year. Median survival was 12 months for patients treated with radiotherapy plus chemotherapy and 9.4 months for patients treated with radiation only.
The concept of radiotherapy administered concomitantly with chemotherapy has been explored by using several agents with radiosensitizing properties but the results were not encouraging [38] [39] [40] [41] . Kleinberg et al. reported a median survival of 12.8 months for patients treated with concomitant radiotherapy plus cisplatin and BCNU
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The combined use of concomitant TMZ and radiation followed by adjuvant TMZ had been confirmed in two important randomized trials 2, 23 . Both trials had the same design. An EORTC phase III trial 23 included 573 patients while Athanassiou et al. trial 2 included 110 patients with newly diagnosed GBM. In both trials, the patients were randomly assigned to either standard RT (60 Gy in 30 daily fractions of 2 Gy) or the concomitant daily TMZ (75 mg/m 2 /day) and conventionally fractionated irradiation followed by 6 cycles of adjuvant TMZ (200 mg/ m 2 /day for five days every 28 days). In both of these trials, tumor response was not an end point. The tumor responses in our study were not encouraging. No recorded complete response in radiation group. Two patients in the chemoradiation group had complete response. Seven patient (33%) and 10 patients (43.5%) in radiation and chemoradiation groups, respectively, had partial response, the differences were statistically insignificant. This can be explained by the fact that contrast enhancement on CT or MRI, while not a true representation of tumor size as it demonstrates the region of blood brain barrier disruption, is accepted as a surrogate for tumor size. However as the size of region of enhancement is altered by surgery, radiotherapy and by the use of steroids, it is an unreliable measure for tumor response.
Our randomized study confirmed the superiority of the concomitant TMZ and radiation followed by adjuvant TMZ regimen over RT alone, which supports the final data of EORTC 23 and Athanassiou et al. 2 trials. The EORTC trial demonstrated that the combined treatment, compared with RT alone, significantly improved median survival (12 vs. 14.6 months, respectively), median PFS (5 vs. 6.9 months, respectively) and the 2-year overall survival, (10.4% vs. 26.5%, respectively). The Athanassiou et al.
2 trial demonstrated that the combined treatment, compared with RT alone, significantly improved median survival (7.7 vs. 13.4 months, respectively), median PFS (5.2 vs. 10.8 months, respectively), and the 18-months overall survival (5.38% vs. 24.9%, respectively). In the present study, the median survival and the median PFS in the combined group (12.6 months and 10.5 months, respectively) compared significantly with the results of radiation group (8.5 months and 6.3 months, respectively) but still inferior to that reported in EORTC trial. This can be explained by the following factors. First, In EORTC trial, the patients were a relatively healthy group; 64% of patients had a good performance status (Karnofsky >80) compared with only 22% of patient in the present study. Second, 84% of patients underwent debulking surgery in EORTC trial compared to only 52% in our study. Third, dose intensity, temozolomide may be more effective if given on daily basis during radiation as in EORTC trial than on intermittent basis.
In our study, there were a tendency for better overall survival for, healthy patients (performance status > 80), young patients (<50 years old), and those underwent debulking surgery. However, the differences were not statistically significant mainly because of small numbers of patients. The multivariate analysis of prognostic factors in Athanassiou et al. trial 2 demonstrated that the administration of TMZ, age and performance status were the significant prognostic factor for better survival. In EORTC trial 23 , they demonstrated additionally that a significant increase in median survival with debulking surgery compared with biopsy alone.
Grade 3/4 toxicity was not recorded in the radiation group. The incidence of drug-related toxic effects in this study was extremely low and manageable, even when temozolomide was administered concomitantly with radiotherapy. The main side effect in chemoradiation group was myelosuppression that was reversible and noncumulative, which allowed for nearly continuous therapy. Grade 3/4 hematologic toxicity was documented in three patients (13%) during the concomitant course and in 6 patients (26%) during the adjuvant TMZ course. Radiation course interruption, in chemoradiation group, was reported in only three patients (13%) due to toxicity. Nonhematologic adverse effects occurred with low frequency. Grade 3/4 nausea and vomiting were virtually eliminated with standard antiemetics. EORTC trial 23 and Athanassiou et al. trial 2 had the same low toxicity profile.
CONClusiON
The results of our study suggested that concomitant radiation and TMZ followed by 6 cycles of adjuvant TMZ is superior to radiation alone in patients with newly diagnosed GBM. In addition, TMZ was safe and tolerable. Nevertheless, the challenge remains to improve clinical outcomes further.
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